Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu PFS Hits 14.3 Months in PIII for 1st-Line NSCLC
Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) delivered a median progression-free survival (PFS) of 14.3 months versus 8.3 months with standard therapy in a global PIII trial for first-line HER2-mutant advanced non-small cell lung cancer (NSCLC). The detailed data from the 454-patient…
To read the full story
Related Article
- Enhertu Hits PIII Primary Goal in 1st-Line HER2-Mutant NSCLC
August 18, 2026
- Daiichi Sankyo Kicks Off PIII for Enhertu in Frontline NSCLC
December 27, 2021
BUSINESS
- Daiichi-AZ, Summit Team Up on Datroway Combo in Multiple Cancers
October 5, 2026
- Taiho, Cullinan Start US Filing for Zipalertinib-Chemo Combo
October 5, 2026
- Stargardt Diagnosis System Needs Bolstering as Treatment Nears: Expert
October 5, 2026
- AstraZeneca Opens Japan Recruitment for Young Oncologist Program
October 5, 2026
- Cheplapharm to Acquire MA for Kyowa Kirin’s 5-FU Products
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…